Stallergenes' pollen therapy positive in US Phase III study
This article was originally published in Scrip
Stallergenes' sublingual allergy desensitisation product Oralair has met the primary endpoint of the reduction of allergy symptoms in its first US Phase III study. The French biotech company plans to file the drug with the US FDA early next year.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.